After a thought-provoking Science From the Fringe interview —“Conversations with Bryce Nickels: Kevin McKernan (Biotech Entrepreneur)”, recorded on September 29, 2025 — Bryce Nickels invited Kevin McKernan back for a live X Space on October 9 to continue the conversation.
Science from the Fringe is a reader-supported publication. To receive new posts and support our work, consider becoming a subscriber.
The conversation offered listeners a candid look into McKernan’s journey — from early breakthroughs in genome sequencing to founding Medicinal Genomics, where he advanced cannabis research, pushing back against significant legal and regulatory pressures.
Kevin and Bryce then pivoted to the validly of the COVID-19 PCR tests used to drive case counts and death tolls, and raised his many concerns about mRNA vaccines. He explained the crux of the issues including frame-shifting, RNA degradation, DNA contamination, and the discovery of SV40 sequences associated with manufacturing changes — all of which he breaks down for benefit of the non-scientist. This segued into Bryce issuing a public mea culpa for the ultimately incorrect and harmful stances taken during the viral panic.
They also touched on regulatory failures, liability protections, and potential health risks from unvetted vaccine production processes, including inflammation and cancer.
The conversation emphasized the importance of scientific transparency over institutional dogma and featured contributions from Kevin’s collaborator Jessica Rose.
Timestamps
00:00:31 — Welcome and host introduction00:01:00 — Introducing Kevin McKernan and his career background00:01:40 — Early career in pharma marketing before the Human Genome Project00:02:07 — Founding Agincourt Biosciences; acquisition and spin-offs00:03:40 — Evolution from Sanger to next-gen sequencing; cost breakthroughs00:06:49 — Launching Medicinal Genomics inspired by cancer patients and cannabinoids00:09:06 — Personalized medicine vs. pandemic-era management00:11:25 — Legal and logistical challenges sequencing cannabis00:12:19 — Sequencing the first cannabis genome (2011) and later improvements00:13:45 — Entering COVID debates via flawed PCR testing00:15:03 — Using crypto to fund peer review, ensuring independence00:17:05 — How prohibition stunted cannabis breeding and diversity00:21:01 — Professional backlash from vaccine research00:24:23 — Discovering vaccine DNA contamination while troubleshooting RNA-seq00:25:02 — “PCR Gate”: Corman-Drosten paper flaws and case inflation00:29:31 — PCR amplification, CT thresholds, and false positives00:32:40 — Infectiousness cutoff at CT 32 and misinterpretation of results00:35:57 — Lessons from pandemic missteps and calls for accountability00:40:47 — Frame-shifting in mRNA vaccines creating unintended proteins00:46:06 — Regulatory neglect around aberrant protein products00:49:21 — RNA integrity issues and template switching00:54:21 — Codon optimization leading to chimeras; later Moderna fix00:59:30 — From trials to mass production: PCR-to-plasmid transitions01:02:09 — Manufacturing changes violating “process is the product” principle01:08:24 — Independent confirmations of excess DNA, including FDA interns01:09:39 — Outdated FDA limits for DNA in lipid nanoparticles01:12:26 — Hidden SV40 sequences; parallels to early polio vaccines01:15:09 — DNA presence undisputed, but effects underexplored01:18:03 — DNA-induced cGAS-STING activation and cancer concerns01:19:26 — Call to sequence all vaccines; outdated contamination limits01:22:02 — How liability shields enable unsafe practices01:26:50 — Fraud case efforts to revoke manufacturer immunity01:37:50 — Future of mRNA tech: potential if transparency restored
intro and outro by Tess Parks
